Drug Trial Radar · NCT02960711
Metformin and Dietary Restriction to Prevent Age-related Morbid Events in People With Metabolic Syndrome
Last checked: Nov 19, 2026Latest source record: Sep 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,600
Actual
Start
Feb 2014
Primary completion
Jul 2019
Study completion Jul 2019
Sponsor
- Lead sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 10, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 55 years, up to 74 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase III randomized controlled trial on men and women with Metabolic syndrome (MetS) to test the hypothesis that comprehensive life-style changes and/or metformin treatment prevent age-related chronic non-communicable diseases (ArCD). The aim of the present study is to evaluate the effect of a comprehensive life-style intervention (including moderate physical activity and Mediterranean/macrobiotic diet with moderate calorie and protein restriction), and of treatment with Metformin (a calorie restriction mimetic drug) for the prevention of ArCD.
Conditions
- Metabolic Syndrome
Interventions
Metformin Hydrochloride 850 MG Oral Tablet [Glucophage]Drug
Ludipress, mg stereate, micronized hydrated silica, talcumDrug
Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total incidence of age related chronic diseasesTime frame: 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fondazione IRCCS Istituto Nazionale Tumori
Milan, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.